Syndax Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio47.49
P/S Ratio47.658.47690.79
P/B Ratio3.923.313.712.904.16
Price/Tangible Book3.923.313.712.904.16
Price/FCF40.81
Price/OCF40.63
Enterprise Value Ratios
EV/Revenue30.536.94588.50
EV/EBITDA36.90
EV/EBIT36.96
EV/FCF33.42
Profitability & Returns
Return on Equity (ROE)-0.76%-0.41%-0.34%0.08%-0.52%
Return on Assets (ROA)-0.32%-0.26%-0.20%0.04%-0.25%
Return on Capital Employed (ROCE)-0.55%-0.41%-0.32%0.06%-0.25%
Leverage & Solvency Ratios
Debt/Equity1.200.000.000.050.08
Debt/EBITDA0.79
Debt/FCF0.72
Liquidity Ratios
Current Ratio5.8210.0016.8521.6815.84
Quick Ratio5.769.9616.8121.6215.79
Efficiency Ratios
Asset Turnover0.040.370.01
Yield & Distribution Ratios
Earnings Yield-0.28%-0.11%-0.09%0.02%-0.07%
FCF Yield-0.24%-0.09%-0.08%0.02%-0.07%
Buyback Yield-0.22%-0.16%-0.13%-0.30%-0.35%